Name: Ipratropium Bromide
Brand: Selleck Chemicals
SKU: S1683
Availability: InStock
Rating: 5 (2 reviews)

Jump to

Quality Control

Batch: Purity: 100.00%

100.00

Related Targets	Adrenergic Receptor 5-HT Receptor COX Calcium Channel Histamine Receptor Dopamine Receptor GABA Receptor TRP Channel Cholinesterase (ChE) GluR
Other AChR Inhibitors	PNU-120596 Benzethonium Chloride Arecoline HBr Lycorine Otilonium Bromide Hyoscyamine (-)-Huperzine A (HupA) Nitenpyram Cytisine Palmatine

Solubility

In vitro
Batch:

DMSO : 83 mg/mL (201.27 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 83 mg/mL

Ethanol : 83 mg/mL

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	412.37	Formula	C₂₀H₃₀BrNO₃	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	22254-24-6	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			Smiles	CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.[Br-]

Mechanism of Action

Targets/IC₅₀/Ki	mAChR
In vitro	Ipratropium bromide combined with Formoterol partially protects the lungs against the chronic inflammation and airspace enlargement by reducing neutrophilic infiltration possibly via the inhibition of MMP-9 activity. Ipratropium bromide (1 nM) significantly increases [Ca(2+)](i), decreases forward scatter and increases annexin-V-binding. Ipratropium bromide treatment is followed by slight but significant increase of hemolysis. Ipratropium bromide triggers suicidal erythrocyte death or eryptosis, an effect mainly due to stimulation of Ca(2+)-entry.
In vivo	Ipratropium dry powder inhalation (DPI) at a dose of 2400 mg/horse is an effective bronchodilator in these horses at rest but it has little effect on the airway calibre during the recovery period. Ipratropium significantly attenuates the lung lesions associated with parenchyma inflammatory cell influx and congestion observed in the cadmium treated rats. Ipratropium bromide partially protects the lungs against the inflammation by reducing neutrophilic infiltration. Ipratropium is an antagonist for pre-junctional muscarinic inhibitory receptors on pulmonary parasympathetic nerves and also confirms its potent antagonist actions on post-junctional muscarinic receptors in the airway smooth muscle in the guinea-pig. Ipratropium decreases the maximal change in pleural pressure during tidal breathing (delta Pplmax) and pulmonary resistance (RL) and increases dynamic compliance (Cdyn) in horse.
References	[1] https://pubmed.ncbi.nlm.nih.gov/20826145/ [2] https://pubmed.ncbi.nlm.nih.gov/23235556/ [3] https://pubmed.ncbi.nlm.nih.gov/9952325/ [4] https://pubmed.ncbi.nlm.nih.gov/19925785/ [5] https://pubmed.ncbi.nlm.nih.gov/2958300/ [6] https://pubmed.ncbi.nlm.nih.gov/8354215/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06110481	Recruiting	Bronchopulmonary Dysplasia\|Chronic Lung Disease of Prematurity\|Chronic Lung Disease of Newborn\|Preterm Birth Complication\|Bronchial Hyperreactivity\|Bronchial Obstruction\|Reversible Dilatation	Charles University Czech Republic	April 1 2021	--
NCT04617015	Completed	Asthma\|Depression\|Childhood Asthma	State University of New York at Buffalo\|National Center for Advancing Translational Sciences (NCATS)	September 9 2016	Early Phase 1
NCT01691079	Completed	Bronchospasm Exercise-Induced	University of California San Francisco	December 2012	Phase 4

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Ipratropium Bromide AChR antagonist

Chemical Structure

Molecular Weight: 412.37